Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin
The Egyptian journal of Immunology · 01.07.2026 · 33 (3) · 65-71
DOI: 10.55133/eji.330307 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Egyptian journal of Immunology, online erschienen am 01.07.2026. Verfasst von Mohamed M Salama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, Galectin 3, Colitis, Ulcerative.
Abstract (Originalsprache)
Inflammatory Bowel Disease (IBD) is a chronic and recurring inflammatory condition of the gastrointestinal system that has an unknown cause and is marked by periods of relapse and remission. Endoscopy remains the gold standard for assessing disease activity; however, noninvasive biomarkers are needed to reduce the burden of repeated invasive procedures. This study aimed to evaluate the role of serum galectin 3 as a biomarker of disease activity in IBD and compare its performance with fecal calprotectin. The study included 40 individuals who were diagnosed with active IBD ulcerative colitis (UC) or Crohn’s disease, and 40 age and sex matched normal controls. Clinical assessment and laboratory investigations which included complete blood picture, C-reactive protein, fecal calprotectin, serum albumin and serum galectin 3 were measured and analyzed. Serum galectin 3 levels were higher in patients with active UC than in clinical remission patients (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Department of Clinical Pathology, Faculty of Medicine - Ain Shams University, Cairo, Egypt.
Zitieren
APA
Salama, M. M., Sayed, M. M., Saad, M. A., Ali, N. Z., Abdelwahed, M. A., & Elessawy, H. A. A. (2026). Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin. The Egyptian journal of Immunology, 33(3), 65-71. https://doi.org/10.55133/eji.330307
Vancouver
Salama MM, Sayed MM, Saad MA, Ali NZ, Abdelwahed MA, Elessawy HAA. Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin. The Egyptian journal of Immunology. 2026;33(3):65-71. doi:10.55133/eji.330307
BibTeX
@article{Salama2026,
author = {Salama, Mohamed M and Sayed, Moataz M and Saad, Mohamed A and Ali, Nancy Z and Abdelwahed, Marwa A and Elessawy, Hagar A A},
title = {Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin},
journal = {The Egyptian journal of Immunology},
year = {2026},
volume = {33},
number = {3},
pages = {65--71},
doi = {10.55133/eji.330307}
}
EUVIMED